Fulgent Genetics, Inc. (FLGT)
NASDAQ: FLGT · Real-Time Price · USD
18.14
-0.10 (-0.55%)
May 29, 2026, 4:00 PM EDT - Market closed
Fulgent Genetics Revenue
Fulgent Genetics had revenue of $71.14M in the quarter ending March 31, 2026, a decrease of -3.16%. This brings the company's revenue in the last twelve months to $320.35M, up 9.54% year-over-year. In the year 2025, Fulgent Genetics had annual revenue of $322.67M with 13.83% growth.
Revenue (ttm)
$320.35M
Revenue Growth
+9.54%
P/S Ratio
1.61
Revenue / Employee
$243,609
Employees
1,315
Market Cap
515.19M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 322.67M | 39.20M | 13.83% |
| Dec 31, 2024 | 283.47M | -5.74M | -1.99% |
| Dec 31, 2023 | 289.21M | -329.76M | -53.27% |
| Dec 31, 2022 | 618.97M | -373.62M | -37.64% |
| Dec 31, 2021 | 992.58M | 570.87M | 135.37% |
| Dec 31, 2020 | 421.71M | 389.18M | 1,196.46% |
| Dec 31, 2019 | 32.53M | 11.18M | 52.35% |
| Dec 31, 2018 | 21.35M | 2.62M | 13.99% |
| Dec 31, 2017 | 18.73M | 454.00K | 2.48% |
| Dec 31, 2016 | 18.28M | 8.70M | 90.85% |
| Dec 31, 2015 | 9.58M | 8.30M | 649.30% |
| Dec 31, 2014 | 1.28M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 829.00M |
| NeoGenomics | 745.97M |
| OPKO Health | 581.12M |
| GeneDx Holdings | 442.68M |
| CareDx | 412.82M |
| Castle Biosciences | 339.92M |
| FONAR | 105.34M |
| Biodesix | 96.10M |
FLGT News
- 8 days ago - Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm - GlobeNewsWire
- 9 days ago - Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting - Business Wire
- 10 days ago - Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 25 days ago - Fulgent Genetics price target lowered to $15 from $30 at Piper Sandler - TheFly
- 26 days ago - Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics - Business Wire
- 4 weeks ago - Fulgent Genetics Earnings Call Transcript: Q1 2026 - Transcripts
- 4 weeks ago - Fulgent Genetics Earnings release: Q1 2026 - Filings
- 4 weeks ago - Fulgent Genetics Slides: Q1 2026 - Filings